Market Overview

Earnings Growth, Execution Fetch Anthem An Upgrade From BMO

Earnings Growth, Execution Fetch Anthem An Upgrade From BMO

Health insurer Anthem Inc (NYSE: ANTM) is a multiregional powerhouse in commercial and Medicaid products, with an aggressive approach toward acquisitions and accretive deployment of capital, according to BMO Capital Markets. 

The Analyst

Analyst Matt Borsch upgraded Anthem from Market Perform to Outperform and increased the price target from $275 to $290.

The Thesis

Anthem can further strengthen its local market share and achieve industry-leading growth thanks to $4 billion in annual pharmacy cost savings, Borsch said in a Monday note. (See the analyst's track record here.) 

Partnerships with other health plans such as non-Anthem Blue Cross plans are contributing to better earnings growth, the analyst said. New fee-based arrangements with health plans and other entities could also help, he said.

The health insurer holds the opportunity for further market share gains if it captures a "substantial share" of $80 billion in expected new Medicaid revenue, Borsch said. 

"We also highlight optionality on several fronts including 'upside only' potential outcomes from pending litigation (ESRX and Cigna) as well as the eventual likelihood of consolidation of other Blue plans by Anthem as scale economics become increasingly important." 

The sell-side firm views the valuation of Anthem shares as attractive.

The Price Action

Anthem shares have gained about 8 percent year-to-date.

The stock was trading up 2.26 percent to $247.64 at the time of publication Monday.

Related Links:

Credit Suisse: Growing Enrollment, 2019 Tailwinds For Humana Justify Bullish Stance

7 Health Care Names Worth Owning In The Trump Age

Latest Ratings for ANTM

Jul 2020Deutsche BankMaintainsBuy
Jul 2020RBC CapitalMaintainsOutperform
Jul 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for ANTM
View the Latest Analyst Ratings


Related Articles (ANTM)

View Comments and Join the Discussion!

Posted-In: BMO Capital Markets Matt BorschAnalyst Color Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga

Latest Ratings

TXRHJP MorganMaintains67.0
SBUXJP MorganMaintains82.0
MCDJP MorganMaintains220.0
CMGJP MorganMaintains1,115.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at